07:00 , Mar 11, 2013 |  BC Week In Review  |  Clinical News

Filgrastim NK regulatory update

Nippon Kayaku said Japan approved Filgrastim NK, a biosimilar of G-CSF, to treat chemotherapy-induced neutropenia (CIN). The product is partnered with Teva. The partners submitted the regulatory application last March (see BioCentury, March 19, 2012)....
02:12 , Mar 5, 2013 |  BC Extra  |  Company News

Japan approves another biosimilar G-CSF

Nippon Kayaku Co. Ltd. (Tokyo:4272) said Japan approved Filgrastim NK, a biosimilar of granulocyte colony-stimulating factor (G-CSF), to treat chemotherapy-induced neutropenia (CIN). The product is partnered with Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), which was unchanged...
08:00 , Jan 2, 2012 |  BC Week In Review  |  Clinical News

G-CSF regulatory update

Mochida and partner Fuji Pharma submitted a regulatory application in Japan for FSK0808, a biosimilar of G-CSF, to treat chemotherapy-induced neutropenia. The pharmas said this is the first application for a biosimilar version of G-CSF...
01:13 , Dec 28, 2011 |  BC Extra  |  Company News

Mochida, Fuji submit application in Japan for G-CSF biosimilar

Mochida Pharmaceutical Co. Ltd. (Tokyo:4534) and partner Fuji Pharma Co. Ltd. (Osaka:4554; JASDAQ:4554) submitted a regulatory application in Japan for FSK0808 , a biosimilar of granulocyte colony-stimulating factor (G-CSF), to treat chemotherapy-induced neutropenia. The pharmas...